Connection

Michael Zile to Guanylyl Cyclase C Agonists

Back to Details
This is a "connection" page, showing publications Michael Zile has written about Guanylyl Cyclase C Agonists.
Michael Zile
Connection Strength
0.042
Guanylyl Cyclase C Agonists
  1. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). Am Heart J. 2020 04; 222:183-190.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.